
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care ...
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ — Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced today optimistic results from its ongoing clinical trial evaluating LAM561 …